Article

LCA Vision has new excimer laser strategy to reduce operating expenses

After following a rigorous clinical comparison of excimer laser platform technologies, LCA Vision is finalizing plans to reduce the number of platforms at each of its LASIKPlus vision centers from three to two.

Cincinnati-After following a rigorous clinical comparison of excimer laser platform technologies, LCA Vision is finalizing plans to reduce the number of platforms at each of its LASIKPlus vision centers from three to two.

The company said it expects this action will reduce annual operating expenses in excess of $3 million when the program is implemented fully no later than the end of the third quarter of 2009. Also new agreements with equipment manufacturers will allow LCA Vision to retire $2.1 million of capital lease obligations immediately.

The excimer treatment platforms will be standardized through 5-year relationships with Abbott Medical Optics Inc. (formerly Advanced Medical Optics Inc.) for two proprietary laser systems (VISX Star SR IR, Abbott Medical Optics; Allegretto Wave Eye-Q 400Hz, Alcon Laboratories).

"We are capitalizing on an opportunity afforded by advancements in excimer laser platforms, which allow us to reduce the number of lasers per center and lower costs while ensuring our continued ability to achieve industry-leading clinical outcomes," said Steven C. Straus, chief executive officer of LCA-Vision.

"We are confident that reducing the number of excimer lasers in each LasikPlus vision center from three to two will have virtually no impact on the patient experience or clinical outcome,” said Lewis Groden, MD, medical advisory board, LCA Vision, Tampa, FL.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.